Search results for "From ACP Journal Club"
Review: In diabetes, benefits of lowering BP depend on baseline BP being 140 mm Hg or more
Hypertension treatment reduced mortality and myocardial infarction in diabetic patients with a systolic blood pressure of at least 140 mm Hg, a systematic review and meta-analysis found. However, in patients with lower baseline blood pressure (BP), treatment didn't affect overall mortality and was associated with increased cardiovascular mortality.
https://diabetes.acponline.org/archives/2016/07/15/6.htm
15 Jul 2016
Review: In diabetes, intensive and standard glycemic control do not differ for end-stage kidney disease or death
The review suggests that treating diabetes with strict glycemic control does not reduce mortality or cardiovascular risk or slow progression of kidney disease, and the results question whether strict glycemic control for preventing any complications is warranted, ACP Journal Club authors wrote.
https://diabetes.acponline.org/archives/2017/11/10/8.htm
10 Nov 2017
In abstinent adults with type 2 diabetes, a daily glass of wine (vs mineral water) improved cardiometabolic factors
Drinking red wine, rather than mineral water, with dinner every night for 2 years was associated with improvements in cholesterol markers in patients in Israel. A group assigned to white wine did not show significant differences on these markers from the water group.
https://diabetes.acponline.org/archives/2016/03/11/6.htm
11 Mar 2016
Review: Intensive blood pressure control reduces retinopathy in diabetes
Intensive control of blood pressure reduced incidence of retinopathy, but not progression of established retinopathy, in patients with type 1 or 2 diabetes, according to an analysis of 15 randomized controlled trials.
https://diabetes.acponline.org/archives/2015/07/10/5.htm
10 Jul 2015
In type 1 diabetes, adding liraglutide to insulin increased hypoglycemia and hyperglycemia with ketosis
The study authors concluded that the negative effects observed would limit clinical use of liraglutide in patients with type 1 diabetes.
https://diabetes.acponline.org/archives/2017/01/13/6.htm
13 Jan 2017
In insulin-treated type 1 diabetes, canagliflozin increased diabetic ketoacidosis
Taking canagliflozin, at a dose of either 100 mg or 300 mg per day, was associated with risk of diabetic ketoacidosis, according to a trial that randomized patients with type 1 diabetes to either of the doses or a placebo.
https://diabetes.acponline.org/archives/2016/08/12/5.htm
12 Aug 2016
Review: Sulfonylureas are associated with overall mortality and CV events vs other antihyperglycemics
A review looked at randomized trials that compared mortality rates among patients taking sulfonylureas versus several other classes of hypoglycemic drugs.
https://diabetes.acponline.org/archives/2017/05/12/6.htm
12 May 2017
Review: Metformin is linked to reduced mortality in type 2 diabetes with comorbid CKD and CHF
The included studies focused on metformin use in patients with chronic kidney disease (CKD), congestive heart failure (CHF), chronic liver disease (CLD), or older age.
https://diabetes.acponline.org/archives/2017/05/12/7.htm
12 May 2017
Bariatric surgery improved HbA1c more than intensive medical therapy in obese patients with uncontrolled type 2 DM
Longer-term outcomes show that adding Roux-en-Y gastric bypass (RYGB) or sleeve gastrectomy to intensive medical therapy enabled more obese, type 2 diabetes patients to maintain glycemic control.
https://diabetes.acponline.org/archives/2014/09/12/6.htm
12 Sep 2014
In patients with type 2 diabetes and high CV risk, liraglutide reduced a composite CV outcome at a median 3.8 y
The study's primary composite outcome was first occurrence of death from cardiovascular (CV) causes, nonfatal (including silent) myocardial infarction, or nonfatal stroke.
https://diabetes.acponline.org/archives/2016/11/11/6.htm
11 Nov 2016